Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

RYAN S DRAKE

Allopathic & Osteopathic Physicians Psychiatry & Neurology Neurology

NPI
1326256462
CMS profile
105950
Location
CANTON, OH

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$31,680.53

239 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

By paying entity

PY2019 · entire year · sorted by reported total

Page 5 of 5; records 201–239 of 239 matching records. This page contains 39 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

RYAN S DRAKE

NPI 1326256462 · CMS profile ID 105950

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Neurology

CANTON, OH

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 5 of 5; records 201–239 of 239 matching records. This page contains 39 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1326256462?year=2019&recipient=provider&page=5#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
RYAN S DRAKE, NPI 1326256462, CMS profile ID 105950. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 5 of 5; records 201–239 of 239 matching records. This page contains 39 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1326256462?year=2019&recipient=provider&page=5#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). RYAN S DRAKE, NPI 1326256462, CMS profile ID 105950. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 5 of 5; records 201–239 of 239 matching records. This page contains 39 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1326256462?year=2019&recipient=provider&page=5#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
RYAN S DRAKE, NPI 1326256462, CMS profile ID 105950, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 5 of 5; records 201–239 of 239 matching records. This page contains 39 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1326256462?year=2019&recipient=provider&page=5#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

239 matching records · $31,680.53 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 239 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 201–239 of 239.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Teva Pharmaceuticals USA, Inc. $103.0703/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697859691 CMS
Amgen Inc. $13.5703/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662985607 CMS
GENZYME CORPORATION $20.5603/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 694016387 CMS
Vanda Pharmaceuticals Inc. $18.7403/08/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697672751 CMS
EISAI INC. $18.1503/06/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697000531 CMS
Strongbridge US INC. $12.4903/05/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688230005 CMS
Teva Pharmaceuticals USA, Inc. $8.1903/05/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697693781 CMS
Amgen Inc. $18.0703/01/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662985601 CMS
Neos Therapeutics, LP $22.2202/28/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 705631409 CMS
Genentech USA, Inc. $12.3302/27/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681193247 CMS
Bausch Health US, LLC $21.7802/25/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 684522893 CMS
GENZYME CORPORATION $18.9802/25/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 693947401 CMS
ACADIA Pharmaceuticals Inc $16.0002/21/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 699999877 CMS
Lundbeck LLC $22.3902/21/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 684293433 CMS
Sunovion Pharmaceuticals Inc. $12.6202/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688120507 CMS
Novartis Pharmaceuticals Corporation $12.7902/13/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659137561 CMS
UCB, Inc. $14.2602/13/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688260365 CMS
GENZYME CORPORATION $16.5802/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 693933037 CMS
Neurocrine Biosciences, Inc. $12.2602/07/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 693124875 CMS
Novartis Pharmaceuticals Corporation $17.0702/07/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658813498 CMS
EMD Serono, Inc. $15.5002/06/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 702987715 CMS
Teva Pharmaceuticals USA, Inc. $4.9702/06/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697765297 CMS
GE HEALTHCARE $12.0602/04/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 698469697 CMS
Acorda Therapeutics, Inc $24.3501/31/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 633491269 CMS
Novartis Pharmaceuticals Corporation $15.5001/31/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659137557 CMS
Novartis Pharmaceuticals Corporation $17.8001/30/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659137471 CMS
ACADIA Pharmaceuticals Inc $15.6501/29/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 699999875 CMS
EMD Serono, Inc. $21.9501/29/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 702969917 CMS
Avanir Pharmaceuticals, Inc. $15.2901/25/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 653586641 CMS
Lilly USA, LLC $11.2401/17/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658145309 CMS
Sunovion Pharmaceuticals Inc. $9.3001/16/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688120503 CMS
Sunovion Pharmaceuticals Inc. $3.0001/16/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688120505 CMS
Vertical Pharmaceuticals, LLC $15.5001/16/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 675498705 CMS
Novartis Pharmaceuticals Corporation $17.0001/15/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658813493 CMS
Amgen Inc. $19.8301/14/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662985595 CMS
UCB, Inc. $10.5801/09/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688253411 CMS
GENZYME CORPORATION $15.3301/08/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 693892001 CMS
GENZYME CORPORATION $19.3501/07/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 693892467 CMS
Teva Pharmaceuticals USA, Inc. $15.1301/07/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697679051 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $31,680.53 239
PY2020 $52,908.26 225
PY2021 $44,408.28 233
PY2022 $49,428.65 306
PY2023 $18,709.34 284
PY2024 $63,143.89 338
PY2025 $89,482.81 386

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $3,300.21 1
PY2025 Principal investigator $1,862,555.01 156
PY2024 Recipient $2,391.00 2
PY2024 Principal investigator $572,163.21 71
PY2023 Recipient $2,174.61 3
PY2023 Principal investigator $856,409.21 71
PY2022 Recipient $8,362.00 5
PY2022 Principal investigator $1,023,208.08 63
PY2021 Recipient $43,138.83 3
PY2021 Principal investigator $489,576.76 38
PY2020 Recipient $15,475.00 1
PY2020 Principal investigator $124,453.12 39
PY2019 Principal investigator $186,020.47 93

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

157 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Alnylam Pharmaceuticals Inc. $48.00 12/31/2025 Non-covered Recipient Entity
NeuroCare Center
A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) No dispute reported 06/30/2026 1215507099
Principal investigator 1 Avadel CNS Pharmaceuticals, LLC $31,192.68 12/31/2025 Covered Recipient Teaching Hospital
INDIANA UNIVERSITY HEALTH
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL, MULTICENTER STUDY OF THE EFFICACY AND SAFETY OF FT218 IN THE TREATMENT OF IDIOPATHIC HYPERSOMNIA (IH) No dispute reported 06/30/2026 1208554177
Principal investigator 1 Avadel CNS Pharmaceuticals, LLC $26,040.70 12/31/2025 Non-covered Recipient Entity
NEUROCARE CENTER INC
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL, MULTICENTER STUDY OF THE EFFICACY AND SAFETY OF FT218 IN THE TREATMENT OF IDIOPATHIC HYPERSOMNIA (IH) No dispute reported 06/30/2026 1208554205
Principal investigator 1 Avadel CNS Pharmaceuticals, LLC $52,123.53 12/31/2025 Non-covered Recipient Entity
ABINGTON NEUROLOGICAL ASSOCIATES LTD
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL, MULTICENTER STUDY OF THE EFFICACY AND SAFETY OF FT218 IN THE TREATMENT OF IDIOPATHIC HYPERSOMNIA (IH) No dispute reported 06/30/2026 1208554207
Principal investigator 1 Avadel CNS Pharmaceuticals, LLC $44,770.00 12/31/2025 Non-covered Recipient Entity
GEISINGER CLINIC
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL, MULTICENTER STUDY OF THE EFFICACY AND SAFETY OF FT218 IN THE TREATMENT OF IDIOPATHIC HYPERSOMNIA (IH) No dispute reported 06/30/2026 1208554209
Principal investigator 1 Alkermes, Inc. $70.00 12/23/2025 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH CENTER, LLC.
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208625015
Principal investigator 1 Alkermes, Inc. $2,413.00 12/10/2025 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH CENTER, LLC.
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208621416
Principal investigator 1 Alkermes, Inc. $650.00 12/01/2025 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH CENTER, LLC.
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208624582
Principal investigator 1 Novartis Pharmaceuticals Corporation $30.00 12/01/2025 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH CENTER .
A randomized, double-blind, placebo-controlled phase III study to evaluate the efficacy, safety, and tolerability of iptacopan in patients with generalized Myasthenia Gravis (gMG), followed by an open label extension phase No dispute reported 06/30/2026 1190311747
Principal investigator 1 Alkermes, Inc. $2,361.00 11/10/2025 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH CENTER, LLC.
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208617137
Principal investigator 1 Alkermes, Inc. $424.00 11/10/2025 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH CENTER, LLC.
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208618217
Principal investigator 1 Alkermes, Inc. $54.72 11/07/2025 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH CENTER, LLC.
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208617365
Recipient Amneal Pharmaceuticals LLC $3,300.21 11/06/2025 Covered Recipient Physician IPX203-401-23 No dispute reported 06/30/2026 1220530589
Principal investigator 1 Alkermes, Inc. $1,500.00 11/05/2025 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH CENTER, LLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208615041
Principal investigator 1 Alkermes, Inc. $2,000.00 11/05/2025 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH CENTER, LLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208622279
Principal investigator 1 Alnylam Pharmaceuticals Inc. $48.00 10/31/2025 Non-covered Recipient Entity
NeuroCare Center
A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) No dispute reported 06/30/2026 1215507090
Principal investigator 1 Alnylam Pharmaceuticals Inc. $48.00 10/28/2025 Non-covered Recipient Entity
NeuroCare Center
A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) No dispute reported 06/30/2026 1215507095
Principal investigator 1 Alkermes, Inc. $250.00 10/27/2025 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH CENTER, LLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208618487
Principal investigator 1 Eisai Inc. $2,532.70 10/20/2025 Non-covered Recipient Entity
Neuroscience Research Center
A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 1244560228
Principal investigator 1 Alkermes, Inc. $250.00 10/17/2025 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH CENTER, LLC.
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208624530
Principal investigator 1 Alkermes, Inc. $250.00 10/15/2025 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH CENTER, LLC.
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208616919
Principal investigator 1 Alkermes, Inc. $250.00 10/08/2025 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH CENTER, LLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208615849
Principal investigator 1 Alkermes, Inc. $2,884.00 10/08/2025 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH CENTER, LLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208620143
Principal investigator 1 Alkermes, Inc. $1,200.00 10/08/2025 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH CENTER, LLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208622069
Principal investigator 1 Alkermes, Inc. $650.00 10/08/2025 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH CENTER, LLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208622565
Principal investigator 1 Alkermes, Inc. $346.00 10/03/2025 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH CENTER, LLC.
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208615603
Principal investigator 1 Alkermes, Inc. $1,350.00 10/03/2025 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH CENTER, LLC.
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208618931
Principal investigator 1 Alkermes, Inc. $346.00 10/03/2025 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH CENTER, LLC.
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208626676
Principal investigator 1 Alkermes, Inc. $519.08 10/02/2025 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH CENTER, LLC.
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208618213
Principal investigator 1 Alkermes, Inc. $150.00 10/01/2025 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH CENTER, LLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208618219
Principal investigator 1 Alnylam Pharmaceuticals Inc. $48.00 09/30/2025 Non-covered Recipient Entity
NeuroCare Center
A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) No dispute reported 06/30/2026 1215506930
Principal investigator 1 Novo Nordisk AS $4,712.38 09/19/2025 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH CENTER, LLC
NN6535-4725 No dispute reported 06/30/2026 1213833611
Principal investigator 1 Alkermes, Inc. $1,500.00 09/17/2025 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH CENTER, LLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208618623
Principal investigator 1 H. Lundbeck A S $325.00 09/10/2025 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH CENTER LLC
A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications No dispute reported 06/30/2026 1251774458
Principal investigator 1 Alkermes, Inc. $2,216.00 09/08/2025 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH CENTER, LLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208612963
Principal investigator 1 Alkermes, Inc. $745.00 09/08/2025 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH CENTER, LLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208613575
Principal investigator 1 Alkermes, Inc. $6,167.00 09/08/2025 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH CENTER, LLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208618841
Principal investigator 1 Alkermes, Inc. $7,947.00 09/08/2025 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH CENTER, LLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208622195
Principal investigator 1 Alkermes, Inc. $17.12 09/04/2025 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH CENTER, LLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208625295
Principal investigator 1 Alkermes, Inc. $1.40 09/04/2025 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH CENTER, LLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208625545
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,500.00 09/04/2025 Non-covered Recipient Entity
NeuroScience Research Center LLC
A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) No dispute reported 06/30/2026 1215506937
Principal investigator 1 Alnylam Pharmaceuticals Inc. $3,200.00 09/04/2025 Non-covered Recipient Entity
NeuroScience Research Center LLC
A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) No dispute reported 06/30/2026 1215506941
Principal investigator 1 Alnylam Pharmaceuticals Inc. $10,000.00 09/04/2025 Non-covered Recipient Entity
NeuroScience Research Center LLC
A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) No dispute reported 06/30/2026 1215506946
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,540.00 09/04/2025 Non-covered Recipient Entity
NeuroScience Research Center LLC
A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) No dispute reported 06/30/2026 1215506950
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,538.00 09/04/2025 Non-covered Recipient Entity
NeuroScience Research Center LLC
A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) No dispute reported 06/30/2026 1215506954
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,910.00 09/04/2025 Non-covered Recipient Entity
NeuroScience Research Center LLC
A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) No dispute reported 06/30/2026 1215506957
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,621.00 09/04/2025 Non-covered Recipient Entity
NeuroScience Research Center LLC
A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) No dispute reported 06/30/2026 1215506962
Principal investigator 1 Alkermes, Inc. $71.60 09/03/2025 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH CENTER, LLC.
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208614004
Principal investigator 1 Alkermes, Inc. $131.60 09/03/2025 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH CENTER, LLC.
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208616377
Principal investigator 1 Alkermes, Inc. $51.75 09/03/2025 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH CENTER, LLC.
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208625033
Principal investigator 1 Alkermes, Inc. $172.25 09/03/2025 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH CENTER, LLC.
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208626338
Principal investigator 1 Alnylam Pharmaceuticals Inc. $48.00 08/29/2025 Non-covered Recipient Entity
NeuroCare Center
A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) No dispute reported 06/30/2026 1215506927
Principal investigator 1 H. Lundbeck A S $250.00 08/26/2025 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH CENTER LLC
A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications No dispute reported 06/30/2026 1251774029
Principal investigator 1 Alkermes, Inc. $1,879.00 08/20/2025 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH CENTER, LLC.
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208616181
Principal investigator 1 Alkermes, Inc. $1,000.00 08/20/2025 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH CENTER, LLC.
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208624192
Principal investigator 1 Alkermes, Inc. $8,000.00 08/20/2025 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH CENTER, LLC.
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208625555
Principal investigator 1 Alkermes, Inc. $70.00 08/13/2025 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH CENTER, LLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208614200
Principal investigator 1 Alkermes, Inc. $346.00 08/11/2025 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH CENTER, LLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208612965
Principal investigator 1 Alkermes, Inc. $7,287.00 08/11/2025 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH CENTER, LLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208615743
Principal investigator 1 Alkermes, Inc. $346.00 08/11/2025 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH CENTER, LLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208617259
Principal investigator 1 Alkermes, Inc. $346.00 08/11/2025 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH CENTER, LLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208617447
Principal investigator 1 Alkermes, Inc. $2,216.00 08/11/2025 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH CENTER, LLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208618361
Principal investigator 1 Alkermes, Inc. $5,984.00 08/11/2025 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH CENTER, LLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208619069
Principal investigator 1 Alkermes, Inc. $2,476.00 08/11/2025 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH CENTER, LLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208621967
Principal investigator 1 Alkermes, Inc. $745.00 08/11/2025 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH CENTER, LLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208622423
Principal investigator 1 Alkermes, Inc. $745.00 08/11/2025 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH CENTER, LLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208626586
Principal investigator 1 Eisai Inc. $3,897.85 08/11/2025 Non-covered Recipient Entity
Neuroscience Research Center
A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 1244560224
Principal investigator 1 Alkermes, Inc. $1.74 08/05/2025 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH CENTER, LLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208614256
Principal investigator 1 Alkermes, Inc. $74.24 08/05/2025 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH CENTER, LLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208615139
Principal investigator 1 Alkermes, Inc. $51.40 08/05/2025 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH CENTER, LLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208625766
Principal investigator 1 Alnylam Pharmaceuticals Inc. $48.00 07/31/2025 Non-covered Recipient Entity
NeuroCare Center
A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) No dispute reported 06/30/2026 1215506922
Principal investigator 1 Eisai Inc. $806.55 07/21/2025 Non-covered Recipient Entity
Neuroscience Research Center
A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 1244560226
Principal investigator 1 Alkermes, Inc. $190.00 07/18/2025 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH CENTER, LLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208621130
Principal investigator 1 Alkermes, Inc. $2,335.00 07/16/2025 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH CENTER, LLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208615331
Principal investigator 1 Alkermes, Inc. $5,046.00 07/16/2025 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH CENTER, LLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208618843
Principal investigator 1 Alkermes, Inc. $3,998.00 07/16/2025 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH CENTER, LLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208620257
Principal investigator 1 Alkermes, Inc. $250.00 07/11/2025 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH CENTER, LLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208614481
Principal investigator 1 H. Lundbeck A S $2,539.00 07/09/2025 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH CENTER LLC
A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications No dispute reported 06/30/2026 1251771910
Principal investigator 1 H. Lundbeck A S $2,475.00 07/09/2025 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH CENTER LLC
A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications No dispute reported 06/30/2026 1251771915
Principal investigator 1 Alnylam Pharmaceuticals Inc. $48.00 06/30/2025 Non-covered Recipient Entity
Neurocare Center Inc Admin Office
A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) No dispute reported 06/30/2026 1215522701
Principal investigator 1 Novo Nordisk AS $960.26 06/23/2025 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH CENTER, LLC
NN6535-4725 No dispute reported 06/30/2026 1213827328
Principal investigator 1 Alkermes, Inc. $34.35 06/18/2025 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH CENTER, LLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208614086
Principal investigator 1 Alkermes, Inc. $27.82 06/18/2025 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH CENTER, LLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208614306
Principal investigator 1 Alkermes, Inc. $25.00 06/18/2025 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH CENTER, LLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208614513
Principal investigator 1 Alkermes, Inc. $5.95 06/18/2025 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH CENTER, LLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208615757
Principal investigator 1 Alkermes, Inc. $21.56 06/18/2025 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH CENTER, LLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208616121
Principal investigator 1 Alkermes, Inc. $3.85 06/18/2025 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH CENTER, LLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208616203
Principal investigator 1 Alkermes, Inc. $51.55 06/18/2025 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH CENTER, LLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208616645
Principal investigator 1 Alkermes, Inc. $50.15 06/18/2025 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH CENTER, LLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208617285
Principal investigator 1 Alkermes, Inc. $46.75 06/18/2025 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH CENTER, LLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208617603
Principal investigator 1 Alkermes, Inc. $8.56 06/18/2025 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH CENTER, LLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208618157
Principal investigator 1 Alkermes, Inc. $33.32 06/18/2025 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH CENTER, LLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208618163
Principal investigator 1 Alkermes, Inc. $12.06 06/18/2025 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH CENTER, LLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208618803
Principal investigator 1 Alkermes, Inc. $17.10 06/18/2025 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH CENTER, LLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208619005
Principal investigator 1 Alkermes, Inc. $5.45 06/18/2025 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH CENTER, LLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208619325
Principal investigator 1 Alkermes, Inc. $127.40 06/18/2025 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH CENTER, LLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208619819
Principal investigator 1 Alkermes, Inc. $74.24 06/18/2025 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH CENTER, LLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208620924
Principal investigator 1 Alkermes, Inc. $51.40 06/18/2025 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH CENTER, LLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208622613
Principal investigator 1 Alkermes, Inc. $32.70 06/18/2025 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH CENTER, LLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208622615
Principal investigator 1 Alkermes, Inc. $192.75 06/18/2025 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH CENTER, LLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208622829
Principal investigator 1 Alkermes, Inc. $1.74 06/18/2025 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH CENTER, LLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208623510
Principal investigator 1 Alkermes, Inc. $127.40 06/18/2025 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH CENTER, LLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208623996
Principal investigator 1 Alkermes, Inc. $74.80 06/18/2025 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH CENTER, LLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208625706
Principal investigator 1 Alkermes, Inc. $12.06 06/18/2025 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH CENTER, LLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208625934
Principal investigator 1 Alkermes, Inc. $162.05 06/18/2025 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH CENTER, LLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208626538
Principal investigator 1 Alkermes, Inc. $16.00 06/18/2025 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH CENTER, LLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208626836
Principal investigator 1 Eli Lilly and Company $241.40 06/09/2025 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH CENTER LLC
A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE No dispute reported 06/30/2026 1187887388
Principal investigator 1 Alkermes, Inc. $113.34 06/06/2025 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH CENTER, LLC.
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208612977
Principal investigator 1 Alkermes, Inc. $52.48 06/06/2025 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH CENTER, LLC.
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208614066
Principal investigator 1 Alkermes, Inc. $259.54 06/06/2025 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH CENTER, LLC.
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208616433
Principal investigator 1 Alkermes, Inc. $77.64 06/06/2025 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH CENTER, LLC.
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208617883
Principal investigator 1 Alkermes, Inc. $119.36 06/06/2025 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH CENTER, LLC.
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208621324
Principal investigator 1 Alkermes, Inc. $95.76 06/06/2025 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH CENTER, LLC.
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208621758
Principal investigator 1 Alkermes, Inc. $56.85 06/06/2025 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH CENTER, LLC.
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208621977
Principal investigator 1 Alnylam Pharmaceuticals Inc. $48.00 05/30/2025 Non-covered Recipient Entity
Neurocare Center Inc Admin Office
A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) No dispute reported 06/30/2026 1215522703
Principal investigator 1 Alkermes, Inc. $500.00 05/19/2025 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH CENTER, LLC.
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208613285
Principal investigator 1 Alkermes, Inc. $1,196.53 05/07/2025 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH CENTER, LLC.
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208623708
Principal investigator 1 H. Lundbeck A S $9,000.00 05/05/2025 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH CENTER LLC
A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications No dispute reported 06/30/2026 1251770040
Principal investigator 1 Eli Lilly and Company $1,359,431.00 05/02/2025 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH CENTER LLC
LONG-TERM REAL-WORLD COMPARATIVE EFFECTIVENESS OF DONANEMAB PLUS USUAL CARE VERSUS USUAL CARE ALONE IN US PATIENTS WITH EARLY SYMPTOMATIC ALZHEIMER'S DISEASE (TRAILBLAZER-REAL US) No dispute reported 06/30/2026 1187884438
Principal investigator 1 Alkermes, Inc. $1,045.00 05/01/2025 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH CENTER, LLC.
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208613517
Principal investigator 1 Alnylam Pharmaceuticals Inc. $48.00 04/30/2025 Non-covered Recipient Entity
Neurocare Center Inc Admin Office
A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) No dispute reported 06/30/2026 1215522705
Principal investigator 1 Alkermes, Inc. $1,879.00 04/23/2025 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH CENTER, LLC.
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208613535
Principal investigator 1 Alkermes, Inc. $1,000.00 04/23/2025 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH CENTER, LLC.
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208615417
Principal investigator 1 Alkermes, Inc. $8,000.00 04/23/2025 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH CENTER, LLC.
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208618255
Principal investigator 1 Novo Nordisk AS $300.00 04/21/2025 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH CENTER, LLC
NN6535-4725 No dispute reported 06/30/2026 1213829408
Principal investigator 1 H. Lundbeck A S $1,000.00 04/02/2025 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH CENTER LLC
A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications No dispute reported 06/30/2026 1251769386
Principal investigator 1 Alnylam Pharmaceuticals Inc. $48.00 03/31/2025 Non-covered Recipient Entity
Neurocare Canton
A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) No dispute reported 06/30/2026 1215505442
Principal investigator 1 Eli Lilly and Company $712.00 03/25/2025 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH CENTER LLC
LONG-TERM REAL-WORLD COMPARATIVE EFFECTIVENESS OF DONANEMAB PLUS USUAL CARE VERSUS USUAL CARE ALONE IN US PATIENTS WITH EARLY SYMPTOMATIC ALZHEIMER'S DISEASE (TRAILBLAZER-REAL US) No dispute reported 06/30/2026 1187884402
Principal investigator 1 Eli Lilly and Company $1,334.60 03/25/2025 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH CENTER LLC
ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY MEASURED BY AMYLOID REDUCTION OF LY3372993 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE No dispute reported 06/30/2026 1187886220
Principal investigator 1 Novartis Pharmaceuticals Corporation $10,244.75 03/17/2025 Non-covered Recipient Entity
NEURO CARE CENTER
A Pilot Open-Label, Randomized, Multi-Center, Parall el-Arm, of Acute vs Delay Ofatumumab Treatment d uring an Acute Multiple Sclerosis Relapse No dispute reported 06/30/2026 1190308158
Principal investigator 1 ABBVIE INC. $7,000.00 03/06/2025 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH CENTER LLC
P22-487 - Real-World Study of ABBV-951 Subcutaneous Infusion to Assess Change in Disease Activity in Adult Participants With Parkinson s Disease No dispute reported 06/30/2026 1202457190
Principal investigator 1 Alkermes, Inc. $115.65 03/03/2025 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH CENTER, LLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208617183
Principal investigator 1 Alnylam Pharmaceuticals Inc. $48.00 02/28/2025 Non-covered Recipient Entity
Neurocare Canton
A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) No dispute reported 06/30/2026 1215505430
Principal investigator 1 Novo Nordisk AS $2,531.75 02/21/2025 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH CENTER, LLC
NN6535-4725 No dispute reported 06/30/2026 1213785381
Principal investigator 1 Alkermes, Inc. $50.00 02/12/2025 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH CENTER, LLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208616949
Principal investigator 1 Alkermes, Inc. $15.39 02/12/2025 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH CENTER, LLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208618023
Principal investigator 1 Alkermes, Inc. $412.40 02/12/2025 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH CENTER, LLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208618027
Principal investigator 1 Alkermes, Inc. $22.50 02/12/2025 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH CENTER, LLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208618959
Principal investigator 1 Alkermes, Inc. $16.00 02/12/2025 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH CENTER, LLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208621873
Principal investigator 1 Alkermes, Inc. $1.71 02/12/2025 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH CENTER, LLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208621901
Principal investigator 1 Alkermes, Inc. $70.40 02/12/2025 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH CENTER, LLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208622543
Principal investigator 1 Alkermes, Inc. $218.45 02/12/2025 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH CENTER, LLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208624332
Principal investigator 1 Alkermes, Inc. $162.05 02/12/2025 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH CENTER, LLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208624548
Principal investigator 1 Alkermes, Inc. $100.30 02/12/2025 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH CENTER, LLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208624774
Principal investigator 1 Alkermes, Inc. $47.75 02/12/2025 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH CENTER, LLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208624788
Principal investigator 1 Eli Lilly and Company $9,743.00 02/04/2025 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH CENTER LLC
A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE No dispute reported 06/30/2026 1187886218
Principal investigator 1 Alnylam Pharmaceuticals Inc. $48.00 01/31/2025 Non-covered Recipient Entity
Neurocare Canton
A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) No dispute reported 06/30/2026 1215505439
Principal investigator 1 Eli Lilly and Company $131.75 01/27/2025 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH CENTER LLC
ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE No dispute reported 06/30/2026 1187885670
Principal investigator 1 Eli Lilly and Company $30,732.00 01/17/2025 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH CENTER LLC
ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE No dispute reported 06/30/2026 1187887386
Principal investigator 1 Alnylam Pharmaceuticals Inc. $95.01 01/15/2025 Non-covered Recipient Entity
Neurocare Canton
A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) No dispute reported 06/30/2026 1215505433
Principal investigator 1 Alnylam Pharmaceuticals Inc. $25.00 01/15/2025 Non-covered Recipient Entity
Neurocare Canton
A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) No dispute reported 06/30/2026 1215505436
Principal investigator 1 Eli Lilly and Company $68,763.00 01/07/2025 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH CENTER LLC
ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY MEASURED BY AMYLOID REDUCTION OF LY3372993 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE No dispute reported 06/30/2026 1187884906
Principal investigator 1 Alkermes, Inc. $15,156.91 01/01/2025 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH CENTER, LLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208627066
Principal investigator 1 Alkermes, Inc. $15,156.91 01/01/2025 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH CENTER, LLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208627068
Principal investigator 1 Alkermes, Inc. $10,678.47 01/01/2025 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH CENTER, LLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208627142
Principal investigator 1 Alkermes, Inc. $16,536.51 01/01/2025 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH CENTER, LLC.
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208627216
Principal investigator 1 Novartis Pharmaceuticals Corporation $10,031.29 01/01/2025 Non-covered Recipient Entity
NEUROSCIENCE RESEARCH CENTER .
A randomized, double-blind, placebo-controlled phase III study to evaluate the efficacy, safety, and tolerability of iptacopan in patients with generalized Myasthenia Gravis (gMG), followed by an open label extension phase No dispute reported 06/30/2026 1190312743